BPC-157 for Gut Health: What the Research Reports

What is BPC-157 and why is it linked to the gut?

BPC-157 is a lab-made peptide of 15 amino acids that traces back to the digestive tract, which is why so much of its research is about gut tissue.

The name stands for "Body Protection Compound 157." Researchers isolated the parent sequence from a protein present in human gastric juice, then made a stable synthetic version (Sikiric et al., Gut and Liver 2020, PMID 31158953). That origin matters for two reasons. First, it points research toward the gut. Second, the peptide is reported to stay intact in gastric juice, which is unusual, because most peptides are broken down there (Sikiric et al., 2020). That stability is one reason some studies test oral and intragastric routes. It is worth being clear about what BPC-157 is not: it is not a hormone, not a probiotic, not a steroid, and not an approved medicine. It is a research compound, and the digestive findings below come mostly from animals.

How does BPC-157 work in the digestive tract?

Research describes a "cytoprotection" effect, meaning it helped protect and repair the lining of the gut, largely by supporting blood vessel growth and the nitric oxide system.

The core idea in this literature is cytoprotection, a concept for how the stomach protects its own cells, extended by these authors to the whole gut and other organs (Sikiric et al., Gut and Liver 2020, PMID 31158953). At the tissue level, the best-documented mechanism is pro-angiogenic: BPC-157 promoted new blood vessel growth through the VEGFR2 receptor and the nitric oxide (Akt-eNOS) pathway (Sikiric et al., 2020). A healing gut lining needs blood supply, so building vessels and modulating nitric oxide is a plausible route to the repair effects seen in animals. The colocutaneous fistula study made the nitric oxide link explicit, tying BPC-157's healing of a gut-to-skin defect to the nitric oxide system (Klicek et al., J Pharmacol Sci 2008;108(1):7-17, doi:10.1254/jphs.FP0072161). None of this is a proven mechanism in the human gut. It is what animal and cell studies describe.

What does research report on BPC-157 for gut health?

Animal studies report protection against ulcers, healing of experimental colitis, and better healing of surgical connections and fistulas in the gut, but these are not outcomes proven in people.

The gut evidence is broad. On the stomach side, BPC-157 protected against induced gastric ulcers in rats (Xue et al., World J Gastroenterol 2004;10(7):1032-6, PMID 15052688), and the Sikiric review catalogs animal work across gastric and duodenal ulcers, esophagitis, short bowel syndrome, and cecal injury (Sikiric et al., Gut and Liver 2020, PMID 31158953).

On the lower gut, two lines stand out. In a rat colitis model (cysteamine-induced), BPC-157 given by injection or by mouth healed both the colitis and a colon-to-colon surgical join, at doses of 10 mcg/kg or 10 ng/kg (Klicek et al., J Physiol Pharmacol 2013;64(5):597-612, PMID 24304574). In a separate rat model, it improved healing of an ileum-to-ileum surgical connection, reducing swelling and inflammatory cells and increasing collagen and new lining (Vuksic et al., Surg Today 2007;37(9):768-77, doi:10.1007/s00595-006-3498-9, PMID 17713731). It also helped close a persistent colocutaneous fistula in rats (Klicek et al., J Pharmacol Sci 2008, doi:10.1254/jphs.FP0072161). A related thread is the muscle of the gut: in rats, common anti-inflammatory drugs (NSAIDs) weakened the pressure of the lower esophageal and pyloric sphincters, and BPC-157 restored that pressure toward normal (Vitaic et al., J Physiol Pharmacol 2017;68(2):265-72, PMID 28614776).

The honest limitation, stated plainly: nearly all of this is animal data. There is one notable exception worth naming. BPC-157 (under the codes PL-10 and PL14736) entered early human clinical testing as a candidate for ulcerative colitis, and the Sikiric review reports it was safe in those inflammatory bowel disease trials (Sikiric et al., Gut and Liver 2020, PMID 31158953; Vuksic et al., Surg Today 2007, PMID 17713731). "Safe in early trials" is not the same as "proven to work in people," and no large controlled trial has established a gut benefit in humans. Treat the animal findings as hypotheses about people, not proof.

Is there a gut-brain angle to BPC-157?

Some researchers propose that BPC-157 acts on the gut-brain axis, the two-way signaling between the digestive tract and the nervous system, but this is early animal-level theory.

The gut and brain talk to each other constantly through nerves, hormones, and immune signals, and a gastric peptide is a natural candidate to sit in that conversation. Two reviews lay out the case. The first argues that peripherally given BPC-157 reached and influenced the central nervous system and modulated the serotonin and dopamine systems in animals (Sikiric et al., Curr Neuropharmacol 2016;14(8):857-65, PMID 27138887, doi:10.2174/1570159x13666160502153022). A more recent review extends this to both directions, brain-to-gut and gut-to-brain, again through cytoprotective and vascular mechanisms, and states plainly that the supporting evidence is from rats and mice with no human clinical data (Sikiric et al., Pharmaceuticals (Basel) 2023;16(5):676, PMID 37242459, doi:10.3390/ph16050676). This is an interesting research direction, not an established human effect. If you see "gut-brain" claims presented as fact for people, they run ahead of the evidence.

What does BPC-157 gut research report on dosing?

The ranges below reflect what published studies report. This is educational, not a prescription or a personal recommendation.

Most published gut dosing comes from rat studies, where doses are given per kilogram of body weight (for example micrograms per kilogram, written mcg/kg, or nanograms per kilogram, ng/kg). Animal per-kilogram doses do not translate directly to a human dose, and there is no established, trial-validated human dose for gut use. The table shows what specific studies used, with the source for each.

These are the per-kilogram amounts reported in the cited animal studies, provided for reference only. There is no validated conversion to a human dose, and none of these figures should be read as a dosing instruction.

Does BPC-157 affect leaky gut?

Some animal work touches on gut-barrier integrity, but there is no human evidence that BPC-157 treats "leaky gut."

On the gut barrier (the "leaky gut" idea, meaning increased permeability of the intestinal lining), the strongest signal is indirect: BPC-157 counteracted the gut damage that NSAIDs cause in rats and helped restore gut-muscle function after that damage (Vitaic et al., J Physiol Pharmacol 2017, PMID 28614776; Sikiric et al., Gut and Liver 2020, PMID 31158953). "Leaky gut" as a stand-alone human diagnosis is not something these peptide studies establish. The barrier findings are animal-level and indirect, so they should not be read as evidence of a human permeability treatment.

What are BPC-157's side effects and safety profile?

Rodent studies report a wide tolerated dose range, but there is no full human safety profile.

On safety, rodent studies generally report BPC-157 as well tolerated across a wide dose range, and the early human colitis trials were reported as safe (Sikiric et al., Gut and Liver 2020, PMID 31158953). That rests on animal data plus limited human exposure, so it is not a full human safety profile. Practical points that apply to any research compound: injection-site reactions are possible with injected forms, and product purity matters, which is why a certificate of analysis is worth reviewing (see /coa). One mechanism-based caution researchers raise: because BPC-157 promotes new blood vessels, care is warranted in the setting of tumors, which also rely on new vessels (Sikiric et al., Gut and Liver 2020, PMID 31158953). This is a theoretical caution, not a documented human harm.

How is BPC-157 taken in gut research?

Gut studies use injected, oral, and intragastric routes in animals, but oral absorption in people is not established.

Some gut research uses oral or intragastric routes because BPC-157 is reported to be stable in gastric juice (Sikiric et al., Gut and Liver 2020, PMID 31158953). The one published pharmacokinetic study did not measure oral bioavailability, and BPC-157 cleared from blood within minutes in animals (He et al., Front Pharmacol 2022, PMID 36588717), so how well it is absorbed by mouth in people is not established. As with any research compound, route and formulation questions in humans are unresolved, and this section describes what studies used rather than how a person should take it.

Is BPC-157 FDA approved for gut health?

No. The U.S. Food and Drug Administration has not approved BPC-157 for any use.

Its compounding status has been under review, and the review is ongoing. In 2023 the FDA placed BPC-157 into Category 2 of its Section 503A bulk drug substances review, the group flagged for significant safety risks or insufficient data; in April 2026 the FDA removed BPC-157 from that Category 2 list pending a further Pharmacy Compounding Advisory Committee review, which is not the same as approval (FDA, Section 503A bulk drug substances program). Either way, BPC-157 remains an unapproved, investigational compound; consult the FDA program page for the current status. Being under review, or off a review list, is not the same as being approved, and no FDA action has established a gut benefit in people.

For the full mechanism, pharmacokinetics, and side-effect picture, see /bpc-157. For the tissue-repair contrast, see /bpc157-vs-tb500 and /peptides-for-recovery. For peptide basics, see /what-are-peptides.